Key Points
- Emergent Biosolutions SVP Paul Williams sold 3,000 shares at an average price of $6.53, generating $19,590. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, leaving him with 156,098 shares.
- Emergent reported quarterly EPS of $0.60, exceeding the analyst estimate of a $0.08 loss, while revenue of $234.3 million surpassed the $177.5 million consensus forecast.
- Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $10.00; institutional investors own approximately 78.4% of the company’s stock.
Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) SVP Paul Williams sold 3,000 shares of the stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $6.53, for a total value of $19,590.00. Following the sale, the senior vice president directly owned 156,098 shares in the company, valued at $1,019,319.94. This represents a 1.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Emergent Biosolutions Stock Performance
NYSE EBS opened at $7.24 on Tuesday. The firm has a market capitalization of $371.25 million, a P/E ratio of -2.04 and a beta of 2.28. The stock has a 50-day simple moving average of $6.11 and a two-hundred day simple moving average of $7.48. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.95 and a current ratio of 5.42. Emergent Biosolutions Inc. has a fifty-two week low of $4.36 and a fifty-two week high of $14.06.
Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.68. The firm had revenue of $234.30 million for the quarter, compared to the consensus estimate of $177.50 million. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%. On average, equities analysts forecast that Emergent Biosolutions Inc. will post 0.13 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on the stock. Zacks Research raised shares of Emergent Biosolutions to a "hold" rating in a research note on Tuesday, August 11th. JPMorgan Chase & Co. initiated coverage on shares of Emergent Biosolutions in a research note on Friday, August 21st. They issued an "underweight" rating for the company. Weiss Ratings raised shares of Emergent Biosolutions from a "sell (d-)" rating to a "sell (d)" rating in a report on Friday, August 21st. Finally, HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Emergent Biosolutions in a research report on Wednesday, September 9th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $10.00.
Check Out Our Latest Stock Analysis on Emergent Biosolutions
Institutional Trading of Emergent Biosolutions
Several institutional investors have recently bought and sold shares of EBS. WINTON GROUP Ltd increased its position in shares of Emergent Biosolutions by 243.2% in the second quarter. WINTON GROUP Ltd now owns 45,744 shares of the biopharmaceutical company's stock valued at $383,000 after buying an additional 32,415 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in Emergent Biosolutions in the 2nd quarter valued at $29,000. Ancora Advisors LLC grew its stake in Emergent Biosolutions by 160.9% in the 2nd quarter. Ancora Advisors LLC now owns 1,067,867 shares of the biopharmaceutical company's stock valued at $8,949,000 after acquiring an additional 658,600 shares during the period. Public Employees Retirement System of Ohio acquired a new stake in Emergent Biosolutions in the 2nd quarter valued at $36,000. Finally, Bank of America Corp DE purchased a new stake in Emergent Biosolutions in the 2nd quarter worth $1,276,000. 78.40% of the stock is owned by institutional investors and hedge funds.
Emergent Biosolutions Company Profile
(
Get Free Report)
Emergent BioSolutions Inc (NYSE:EBS) is a life sciences company focused on developing, manufacturing and supplying medical countermeasures for public health threats, including chemical, biological, radiological and nuclear hazards, as well as infectious diseases. The company serves government agencies, healthcare providers and commercial customers.
Emergent's portfolio has included vaccines, therapeutics and other products used to prevent or treat serious health threats. Its offerings include BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine, along with products such as botulism antitoxin and vaccinia immune globulin.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
